Edgar Filing: V I TECHNOLOGIES INC

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 10-K/A

X ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
------------------------------------------------------
SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended December 29, 2001

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Commission File No. 0-24241

V.I. TECHNOLOGIES, INC.
(Exact name of registrant as specified in its charter)

DELAWARE 11-3238476
------------------------ ----------
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification No.)

134 Coolidge Ave, Watertown, MA 02472
-------------------------------------
(Address of principal executive offices)(Zip code)

Registrant's telephone number, including area code: (617) 926-1551

Securities registered pursuant to Section 12(b) of the Act: None

Securities registered pursuant to Section 12(g) of the Act:

Common Stock, $.01 par value
----------------------------
(Title of class)

Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the registrant was
required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days. Yes [X] No [_]

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405
of Regulation S-K is not contained herein, and will not be contained, to the
best of the registrant's knowledge, in definitive proxy or information
statements incorporated by reference in Part III of this Form 10-K or any
amendment to this Form 10-K. [X]

The aggregate market value of voting common stock held by non-affiliates of the
Registrant, based on the closing price of the common stock on April 15, 2002 as
reported on the Nasdaq National Market, was approximately $66,986,000.

22,745,529
(Number of shares of common stock outstanding as of April 15, 2002)

EXPLANATORY NOTE:

This Annual Report on Form 10-K/A has been filed by the Registrant to
amend the Annual Report on Form 10-K filed by the Registrant on February 11,
2002 to include the information required to be disclosed by Items 10-13 of Form
10-K.

PART III

ITEM 10. DIRECTORS AND EXECUTIVE OFFICERS OF THE REGISTRANT.

(a) Identification of Directors.

Certain information regarding each of our current directors, including
his principal occupation during the past five years and current directorships,
is set forth below.

Class I Directors Continuing in Office Until the 2002 Annual Meeting.

John R. Barr, age 45, joined our company as President, Chief Executive
Officer and a director in November 1997. Previously, Mr. Barr served as
President of North American Operations at Haemonetics Corporation from 1995 to
1997 where he had responsibility for Haemonetics' blood bank, commercial plasma
and blood bank services businesses. He also managed the global manufacturing and
North American research and development functions and served as a member of the
Board of Directors of Haemonetics. Prior to joining Haemonetics in 1990, he held
various positions at Baxter Healthcare Corporation. Mr. Barr has an
undergraduate degree in Biomedical Engineering from the University of
Pennsylvania and an M.M. from the Kellogg School of Management at Northwestern
University.

Richard A. Charpie, Ph.D., age 50, has served as a director since October
1995. Dr. Charpie served as our Chief Executive Officer from August 1997 to
November 1997. He was our Vice President from November 1997 until January 1998.
Dr. Charpie has been the managing general partner of Ampersand Ventures, a
venture capital firm, and all of its affiliated partnerships ("Ampersand") since
he founded Ampersand in 1988 as a spin-off of the venture capital group of
PaineWebber Incorporated. Currently, Dr. Charpie serves as a director of TriPath
Imaging and of several privately held companies. Dr. Charpie holds an M.S. in
Physics and a Ph.D. in Applied Economics and Finance, both from the
Massachusetts Institute of Technology.

Irwin Lerner, age 71, has served as a director since September 1996. He is
the former Chairman of the Board of Directors, Chairman of the Executive
Committee, President and Chief Executive Officer of Hoffmann-LaRoche Inc.,
having retired in September 1993 after being an employee of that company for
over 31 years. Mr. Lerner is the Chairman of the Board of Directors of Medarex,
Inc. and serves as a director on the boards of Humana Inc., Covance Inc. and
Inhale Therapeutic Systems, Inc. He has been a member of the Board of Project
Hope and has chaired the New Jersey Governor's Council for a Drug-Free
Workplace. He served for twelve years on the Board of Pharmaceutical
Manufacturers Association (now PhRMA), including chairing the Association's FDA
Issues Committee and the PMA Foundation. Mr. Lerner has also served on the
Boards of the National Committee for Quality Health Care, the Partnership for
New Jersey and the Center for Advanced Biotechnology and Medicine of Rutgers
University. He received his B.S. and MBA degrees from Rutgers University, where
he is currently the Distinguished Executive-in-Residence at the Graduate School
of Management.

Class II Directors Continuing in Office Until the 2003 Annual Meeting

Jeremy Hayward-Surry, age 59, has served as a director since December 1997.
He has been the President of Pall Corporation, a global company operating in the
fields of filtration, separations and purification, since July 1994 and a member
of its board of directors since April 1993. Mr. Hayward-Surry was also the
Treasurer and Chief Financial Officer of Pall from August 1992 until December
1997 and Executive Vice President of Pall from 1992 to July 1994. Mr.
Hayward-Surry is a Fellow of the Institute of Chartered Accountants in England
and Wales.

Peter D. Parker, age 51, has served as a director since October 1995. After
fourteen years at AMAX, a metals company, Mr. Parker joined Ampersand in 1989 to
lead its first specialty materials venture capital partnership, Ampersand
Specialty Materials Ventures Limited Partnership. Mr. Parker is a general
partner of Ampersand Ventures. He currently serves as a director of Lighting
Technologies International and MicroPack Corporation, and as the Chairman of
Cyclis Pharmaceuticals, Inc. and Protein Ingredient Technologies. He holds an
M.S. in Chemical Metallurgy from Columbia University.

Damion E. Wicker, M.D., age 41, has served as a director since May 1997.
Dr. Wicker is currently a Partner with JPMorgan Partners, formerly Chase Capital
Partners, a global partnership providing private equity. Dr. Wicker received a
B.S. with honors from the Massachusetts Institute of Technology in 1983, an M.D.
from John Hopkins in 1987, and holds an MBA from the Wharton School of the
University of Pennsylvania. Prior to joining JPMorgan Partners in 1993,
Dr. Wicker was President of Adams Scientific and held positions with MBW Venture
Partners and Alexon, Inc. Dr. Wicker was also a Commonwealth Fund Medical Fellow
for the National Institute of Health. Dr. Wicker currently is also a director of
Genomic Solutions, Medichem Life Sciences and several privately-held companies.

Class III Directors Continuing in Office Until the 2004 Annual Meeting

Samuel K. Ackerman, M.D., age 54, has served as a director and Chief
Scientific Officer since November 1999. Dr. Ackerman co-founded Pentose
Pharmaceuticals, Inc. in June 1995 and served as its President, Chief Executive
Officer and director from February 1997 until Pentose's merger with Vitex on
November 12, 1999. Dr. Ackerman became Executive Vice President and Chief
Scientific Officer of Vitex upon the merger and in September 2000 became
Chairman of the Board. He previously served as Vice President, Development and
Regulatory Affairs of OraVax, Inc. from December 1993 to January 1997. From May
1986 to November 1993, he was Senior Vice President, Medical and Regulatory
Affairs of XOMA Corporation and before that directed the Investigational New
Drug Division of the Center for Biologics Evaluation and Research of the Food
and Drug Administration. Dr. Ackerman is currently an operating partner of
Ampersand Ventures as well as President and Chief Executive Officer of Cyclis
Pharmaceuticals, Inc.

David Tendler, age 64, has served as a director since December 1994. From
1994 until September 2000, he served as Chairman of our Board of Directors.
Since September 2000, he has been the Chairman of our Executive Committee. In
1985, Mr. Tendler founded his own international consulting firm, Tendler Beretz
LLC, and has since served as its President and Chief Executive Officer. In 1981,
he was named Chairman and Chief Executive Officer of Phibro Corporation, which
subsequently acquired Salomon Brothers, at which point Mr. Tendler became
Co-Chairman and CEO of Phibro-Salomon. He joined Philipp Brothers (the
predecessor to Englehard Minerals & Chemicals Corp./Phibro Corp.) in 1960,
managed Far Eastern operations for more than seven years, and was promoted to
President of Phibro in 1975. He remains active in the private equity and
consulting businesses, and in various charitable organizations, including
service as a director of BioTechnology General Corporation and a member of the
Board of Trustees and the Executive Committee of the New York Blood Center. Mr.
Tendler has a B.B.A. from the City University of New York.

Doros Platika, M.D., age 49, has served as a director since August 2000.
Dr. Platika is Chairman of the Board of Curis, Inc., a developer of
biotechnology products based on technologies in regenerative medicines. Dr.
Platika was previously President and Chief Executive Officer of Curis from
February 2000 until September 2001. He was the Chief Executive Officer of
Ontogeny, Inc. from July 1996 until Ontogeny's merger into Curis in July 2000.
Prior to joining Ontogeny, Dr.

Platika completed residencies in medicine and neurology at Massachusetts General
Hospital ("MGH") where he rose to Chief Resident. He completed his post-doctoral
study at the Massachusetts Institute of Technology's Whitehead Institute and at
MGH in association with Harvard Medical School. Dr. Platika also served on the
faculties of Harvard Medical School and of Albert Einstein College of Medicine
as head of gene therapy.

Joseph M. Limber, age 49, has served as a director since February 2001. Mr.
Limber is currently the President, Chief Executive Officer and a director of
ACLARA BioSciences, Inc., a developer of assay technologies and lab-on-a-chip
systems for life science research, and has been with ACLARA since 1998. From
1996 to 1998, Mr. Limber was the President and Chief Operating Officer of
Praecis Pharmaceuticals, a biotechnology company focused on the discovery and
development of pharmaceutical products. Prior to this position, he served as
Executive Vice President of SEQUUS Pharmaceuticals, Inc. Mr. Limber also held
management positions in marketing and sales with Syntex Corporation from 1987 to
1992 and with Ciba-Geigy Corporation from 1975 to 1987. Mr. Limber holds a B.A.
from Duquesne University.

(b) Identification of Executive Officers.

Management

Officers are elected annually by our Board of Directors and serve at the
discretion of the Board of Directors. Set forth below is information regarding
our current executive officers who are not also Directors of our company:

Name Age Position
---- --- --------

Thomas T. Higgins 50 Executive Vice President, Operations and Chief Financial Officer
Bernadette L. Alford, Ph.D. 53 Executive Vice President of Development, Regulatory and Clinical Affairs

Thomas T. Higgins has served as Chief Financial Officer and Executive Vice
President, Operations since June 1998. Prior to joining us, Mr. Higgins was with
the Cabot Corporation, a global specialty chemicals company, from 1985 to 1997,
most recently as President of Distrigas of Massachusetts Corporation, a
subsidiary of the Cabot Corporation. Also in 1997, Mr. Higgins was Executive
Vice President and Chief Operating Officer of Cabot's Liquified Natural Gas
Division. From 1989 to 1997, Mr. Higgins served the Cabot Corporation in Asia,
as Vice President and General Manager of the Pacific Asia Carbon Black Division
in Malaysia (1996-1997), managing director in Indonesia (1990-1995) and director
of New Ventures in Japan (1989-1990). Previously, Mr. Higgins was with Price
Waterhouse. Mr. Higgins holds a B.B.A. from Boston University.

Bernadette L. Alford, Ph.D. joined us in May 2000 and became Executive Vice
President of Development, Regulatory and Clinical Affairs in September 2000.
Prior to joining us, Dr. Alford was Vice President, Regulatory Affairs, of
Biopure Corporation, a developer, manufacturer and supplier of oxygen
therapeutics, where she was responsible for Biopure's regulatory and quality
functions between September 1998 and May 2000. From 1994 to 1998 Dr. Alford was
Senior Vice President, Product Development at Alexion Pharmaceuticals, Inc.
where she was responsible for clinical and regulatory affairs, compliance and
validation for the company's immunoregulatory therapeutics. Dr. Alford received
a Ph.D. in molecular biology and biochemistry from Texas University and has also
received fellowships from the Massachusetts Institute of Technology and Baylor
College of Medicine.

Not applicable.

(d) Family Relationships.

There are no family relationships between any director, executive
officer, or person nominated or chosen by us to become a director or executive
officer.

(e) Business Experience.

The business experience of our executive officers who also serve as our
directors is set forth in Item 10(a) - Identification of Directors of this
Annual Report on Form 10-K/A and the business experience of those executive
officers who are not also our directors is set forth in Item 10(b)-
Identification of Executive Officers of this Annual Report on Form 10-K/A.

The directorships held by each of our directors in any company with a
class of securities registered pursuant to Section 12 of the Securities Exchange
Act of 1934, as amended, or subject to Section 15(d) of such Act or any company
registered as an investment company under the Investment Company Act of 1940, as
amended, is set forth in Item 10(a) of this Annual Report on Form 10-K/A.

(f) Involvement in Certain Legal Proceedings.

To the best of our knowledge, none of our current directors or
executive officers has been involved during the past five years in any legal
proceedings required to be disclosed pursuant to Item 401(f) of Regulation S-K
of the Securities and Exchange Commission.

SECTION 16(a) BENEFICIAL OWNERSHIP REPORTING COMPLIANCE

Section 16(a) of the Exchange Act requires our directors and executive
officers, and persons who own more than ten percent of a registered class of our
equity securities, to file reports of ownership and changes in ownership with
the Securities and Exchange Commission. Directors, executive officers, and
greater than ten percent holders are required by SEC regulations to furnish us
with copies of all Section 16(a) forms they file.

Based solely on our review of the copies of such forms received or
written representations from certain reporting persons, we believe that, during
Fiscal Year 2001 filing requirements under Section 16(a) applicable to our
directors, executive officers and ten percent holders were met.

ITEM 11. EXECUTIVE COMPENSATION.

The following table provides certain summary information concerning
compensation (including salary, bonuses, stock options, and certain other
compensation) paid by us for services in all capacities for fiscal years ended
December 29, 2001, December 30, 2000 and January 1, 2000 to our Chief Executive
Officer and to each of the other persons who served as our executive officers at
December 29, 2001 and whose salary plus bonus exceeded $100,000 in Fiscal Year
2001 (together being hereinafter referred to as the "Named Executive Officers").

SUMMARY COMPENSATION TABLE

Annual Long-Term
Compensation Compensation
------------ ------------

---------------------------------------------------------------------------------------------------------------------
Securities All Other
Name and Underlying Compensation
Principal Position Year Salary($) Bonus($) Options (1) ($) (2)
---------------------------------------------------------------------------------------------------------------------

John R. Barr 2001 $371,087 $ 81,000 75,000 -
President and Chief 2000 361,809 100,000 150,000 -
Executive Officer 1999 324,231 122,500 50,000 -

Thomas T. Higgins 2001 242,230 49,350 50,000 -
Executive Vice 2000 227,956 56,980 100,000 -
President, Operations 1999 199,231 64,759 40,000 -
and Chief Financial Officer

Bernadette L. Alford, Ph.D. 2001 237,980 69,300 50,000 -
Executive Vice President, 2000(3) 116,667 - 150,000 -
Development, Regulatory
and Clinical Affairs

(1) All stock options in this column were granted under the 1998 Equity Plan
which is administered by the Compensation Committee. These options have an
exercise price equal to fair market value on the date of the grant, vest in
four equal annual installments on the first four anniversaries of the date
of grant, and expire ten years from the date of grant.

(2) Excludes perquisites and other personal benefits, securities or property
which, in the aggregate, are less than the lesser of $50,000 or ten percent
(10%) of the total of the annual salary and bonus reported for the Named
Executive Officer for the year.

(3) Dr. Alford joined us in May 2000 and became Executive Vice President,
Development, Regulatory and Clinical Affairs in September 2000. The
information shown in this table for 2000 reflects compensation earned by
Dr. Alford from May 2000 through December 30, 2000.

OPTION GRANTS IN LAST FISCAL YEAR

The following table sets forth information concerning individual grants of
options to purchase common stock made to each Named Executive Officer during
Fiscal Year 2001.

Individual Grants
----------------------------------------------
Potential Realizable Value at
Percent Assumed Annual Rates
Number of of Total of Stock
Securities Options Granted Exercise Price Appreciation
Underlying to Employees in or Base for Option
Options Fiscal Year Price Expiration Term (4)
Name Granted(#)(1) 2001(2) ($/Share) Date (3) 5%($) 10%($)
---- ------------- ------- ------- -------- ----- ------

John R. Barr 75,000 13.8% $6.81 4/5/11 $321,326 $814,303
Thomas T. Higgins 50,000 9.2% $6.75 3/8/11 $212,252 $537,888
Bernadette L. Alford, 50,000 9.2% $6.75 3/8/11 $212,252 $537,888
Ph.D.

(1) See Note (1) to the Summary Compensation Table. The options vest in four
equal annual installments starting on the first anniversary of the grant
date.

(2) Options to purchase an aggregate of 542,629 shares were granted to all our
employees and directors in Fiscal Year 2001.

(3) Options expire ten years from grant date unless the individual earlier
terminates employment. Upon such termination of employment, all vested
options expire 90 days from the termination date.

(4) Amounts reported in these columns represent amounts that may be realized
upon exercise of the options immediately prior to the expiration of their
term assuming the specified compounded rates of appreciation (5% and 10%)
on our common stock over the term of the options. These numbers are
calculated based on rules promulgated by the Securities and Exchange
Commission and do not reflect our estimate of future stock price growth.
Actual gains, if any, on stock option exercises and common stock holdings
are dependent on the timing of such exercise and the future performance of
our common stock. There can be no assurance that the rates of appreciation
assumed in this table can be achieved or that the amounts reflected will be
received by the option holder.

AGGREGATED OPTION EXERCISES AND FISCAL YEAR-END OPTION VALUES

Presented below is information about the number and value of unexercised
stock options to purchase our common stock held by each Named Executed Officer
as of December 29, 2001. No Named Executive Officers exercised any options in
Fiscal Year 2001.

Number of Securities
Underlying Value of Unexercised
Unexercised In-the-Money
Options at Options at
Fiscal Year-End Fiscal Year-End
(#)Exercisable/ ($)Exercisable/
Name Unexercisable Unexercisable(1)

---------------------------------------------------------------------------------------------

John R. Barr 430,121/212,500 -/-
Thomas T. Higgins 170,000/120,000 -/-
Bernadette L. Alford, Ph.D. 37,500/162,500 $8,875 / $26,625

(1) Based on the difference between the option exercise price and the closing
price per share of the underlying common stock on the Nasdaq National
Market on December 28, 2001, which closing price was $6.15.

COMPENSATION OF DIRECTORS

Mr. Tendler received $40,000 for his services as Chairman of our Executive
Committee during Fiscal Year 2001. Messrs. Hayward-Surry and Lerner and Dr.
Platika each received $15,000 for their services as directors. Mr. Limber became
a Board member during Fiscal Year 2001 and received $7,500 for his services.
Each of these Board members also received $2,000 for each meeting of the Board
that they attended. If a committee meeting occurred on days other than when a
Board meeting took place, these directors received $1,000 for each committee
meeting attended.

All members of the Board of Directors receive reimbursement of expenses
associated with their attendance of meetings of the Board of Directors or of any
committee of which they are a member.

In addition, directors who are not also officers or employees received
option grants under the 1998 Director Stock Option Plan, as amended. This plan
provides for an automatic grant of options to purchase 15,000 shares of common
stock upon initial election to the Board of Directors and an automatic annual
grant of options to purchase 2,000 shares of common stock. These grants vest 25
percent on the six-month anniversary of the grant date and then vest 25 percent
each on the second, third and fourth year anniversary of the grant date. The
term of all options granted under the plan, as amended, is ten years from the
date of grant. The exercise price for all options granted under the plan, as
amended, is equal to the last sale price for the common stock on the business
day immediately preceding the date of grant. The exercise price may be paid in
cash or shares.

Pursuant to the 1998 Director Stock Option Plan, Messrs. Tendler, Parker,
Lerner, Limber and Charpie and Drs. Ackerman, Wicker, and Platika each received
an automatic annual option grant on December 14, 2001 to purchase 2,000 shares
of common stock, at an exercise price of $6.80 per share. Mr. Hayward-Surry is
not permitted by his employer to accept option grants and has not received any
grants under the 1998 Director Stock Option Plan.

COMPENSATION COMMITTEE INTERLOCKS AND INSIDER PARTICIPATION

The current members of the Compensation Committee are Messrs. Lerner
and Parker and Dr. Wicker. No member of the Compensation Committee has at any
time been an officer or employer of our company. None of our executive officers
serve as a member of the compensation committee or board of directors of any
other entity which has an executive officer serving as a member of our Board of
Directors or Compensation Committee. Mr. Parker is a general partner of
Ampersand Ventures. Refer to Item 13.

ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT.

SECURITY OWNERSHIP OF MANAGEMENT AND FIVE PERCENT OWNERS

The following table sets forth certain information with respect to
beneficial ownership of our shares of common stock as of April 15, 2002: (i) by
each person (or group of affiliated persons) who we know to own beneficially
more than five percent of our outstanding shares of common stock; (ii) by each
of the Named Executive Officers; (iii) by each of our directors; and (iv) by all
of our current directors and executive officers as a group.

To compute the percentage ownership of any shareholder or group of
shareholders in the following table, the total number of shares deemed
outstanding includes 22,745,529 shares that were outstanding on April 15, 2002,
plus any shares that holder or group of holders could acquire upon exercising
any options held by that holder or group of holders that are exercisable on or
before June 14, 2002. Except as indicated in the footnotes to this table, the
persons named in the table have sole voting and investment power with respect to
all shares shown as beneficially owned by them.

Number of Shares
Name of Beneficial Owner Beneficially Owned (1) Percent of Class
------------------------ ---------------------- ----------------

5% Stockholders
Ampersand Funds(2) 7,637,363 33.6%
55 William Street, Suite 240
Wellesley, MA 02481
New York Blood Center, Inc.(3) 2,009,704 8.8%
310 East 67th Street
New York, NY 10021-6295
J.P. Morgan Partners LLC(4) 1,801,470 7.9%
1221 Avenue of the Americas
New York, NY 10020
Pall Corporation(5) 2,253,022 9.9%
2200 Northern Boulevard
East Hills, NY 11548
Massachusetts Financial Services 1,212,954 5.3%
Company (6)
500 Boylston Street
Boston, MA 02116
State of Wisconsin Investment Board
121 East Wilson Street
Madison, WI 53702 1,666,667 7.3%

Named Executive Officers and
Directors
John R. Barr(7) 498,871 2.1%
Thomas T. Higgins(8) 224,479 *
Bernadette L. Alford, Ph.D(9) 75,000 *
Samuel K. Ackerman, M.D.(10) 429,637 1.9%
Richard A. Charpie(11) 7,653,113 33.6%
Jeremy Hayward-Surry(12) 2,253,022 9.9%
Irwin Lerner(13) 33,638 *
Joseph M. Limber(14) 4,250 *
Peter D. Parker(15) 7,653,113 33.6%
Doros Platika, M.D.(16) 4,750 *
David Tendler(17) 2,030,954 8.9%
Damion E. Wicker, M.D.(18) 1,817,220 8.0%
---------- ----
All current directors and executive 15,024,934 66.1%
officers as a group (12 persons)(19)

* Indicates less than one percent

(1) Beneficial ownership of common stock is determined in accordance with the
rules of the Securities and Exchange Commission, and includes shares for
which the holder has sole or shared voting or investment power. Shares of
our common stock subject to options currently exercisable or which become
exercisable on or before June 14, 2002 are deemed to be beneficially owned
and outstanding by the person holding such options and, in accordance with
the rules of the Securities and Exchange Commission, are included for
purposes of computing the percentage ownership of the person holding such
options, but are not deemed outstanding for purposes of computing the
percentage ownership of any other person.

(2) Consists of 980,000 shares held by Ampersand 1999 Limited Partnership
("AMP-99"), 20,000 shares held by Ampersand 1999 Companion Fund Limited
Partnership ("AMP-99 CF"), 5,029,687 shares held by Ampersand 1995 Limited
Partnership ("AMP-95"), 81,782 shares held by Ampersand 1995 Companion
Fund Limited Partnership ("AMP-95 CF"), 1,052,342 shares held by Ampersand
1992 Limited Partnership ("AMP-92"), 331,487 shares held by Ampersand 1994
Limited Partnership ("AMP-94") and 142,065 shares held by Ampersand 1994
Companion Fund Limited Partnership ("AMP-94 CF").

AMP-99 Management Company Limited Liability Company is the general partner
of AMP-99 and AMP-99 CF. AMP-95 MCLP LLP is the general partner of AMP-95
Management Company Limited Partnership, which itself is the general
partner of both AMP-95 and AMP-95 CF and has voting and investment control
over the shares held by those two entities. AMP-92 MCLP LLP is the general
partner of AMP-92 Management Company Limited Partnership, which itself is
the general partner of AMP-92 and has voting and investment control over
the shares held by AMP-92 . AMP-94 MCLP LLP is the general partner of
AMP-94 Management Company Limited Partnership, which itself is the general
partner of both AMP-94 and AMP-94 CF and has voting and investment control
over the shares held by those two entities. The managing members of AMP-99
Management Company Limited Liability Company who share voting and
investment control over the shares controlled by AMP-99 Management Company
Limited Liability Company are Richard A. Charpie, Peter D. Parker, David
J. Parker, Stuart A. Auerbach and Charles D. Yie. The partners of AMP-95
MCLP LLP, who share voting and investment control over the shares
controlled by AMP-95 MCLP LLP are Richard A. Charpie, Peter D. Parker,
David J. Parker, Stuart A. Auerbach and Charles D. Yie. Richard A.
Charpie, Peter D. Parker, Stuart A. Auerbach, Charles D. Yie and Robert A.
Charpie are the partners of AMP-92 MCLP LLP and AMP-94 MCLP LLP and share
voting and investment control over the shares controlled by those
entities. Richard A. Charpie is the Principal Managing Member of AMP-99
Management Company Limited Liability Company, and the Managing Partner of
AMP-92 MCLP LLP, AMP-95 MCLP LLP, and AMP-94 MCLP LLP. Richard A. Charpie
and Peter D. Parker are our directors.

(3) Mr. Tendler, a director, is a member of the Board of Trustees and
Executive Committee of the New York Blood Center, Inc. ("NYBC").

(4) Dr. Wicker, a director, is a partner at J.P. Morgan Partners LLC.

(5) Mr. Hayward-Surry, a director, is the President and a director of Pall
Corporation.

(6) Based on the information provided in the Schedule 13G filed by
Massachusetts Financial Services Company ("MFS") with the Securities and
Exchange Commission on February 12, 2002. MFS has sole voting power over
1,044,204 shares and sole dispositive power over 1,212,954 shares.

(7) Consists of 498,871 shares issuable upon the exercise of outstanding
options exercisable on or before June 14, 2002.

(8) Consists of 6,979 shares and 217,500 shares issuable upon the exercise of
outstanding options exercisable on or before June 14, 2002.

(9) Consists of 75,000 shares issuable upon the exercise of outstanding
options exercisable on or before June 14, 2002.

(10) Consists of 428,637 shares and 1,000 shares issuable upon the exercise of
outstanding options exercisable on or before June 14, 2002.

(11) Consists of shares described in note (2) of which Dr. Charpie may be
considered the beneficial owner and 15,750 shares issuable upon the
exercise of outstanding options exercisable on or before June 14, 2002.
Dr. Charpie disclaims beneficial ownership of the shares described in note
(2) except to the extent of his pecuniary interest therein.

(12) Consists of 2,253,022 shares held by Pall Corporation, of which Mr.
Hayward-Surry may be considered the beneficial owner. Mr. Hayward-Surry
disclaims beneficial ownership of the shares held by Pall Corporation

(13) Consists of 11,180 shares and 22,458 shares issuable upon the exercise of
outstanding options exercisable on or before June 14, 2002.

(14) Consists of 4,250 shares issuable upon the exercise of outstanding options
exercisable on or before June 14, 2002.

(15) Consists of shares described in note (2) of which Mr. Parker may be
considered the beneficial owner and 15,750 shares issuable upon the
exercise of outstanding options exercisable on or before June 14, 2002.
Mr. Parker disclaims beneficial ownership of the shares described in note
(2) except to the extent of his pecuniary interest therein.

(16) Consists of 4,750 shares issuable upon the exercise of outstanding options
exercisable on or before June 14, 2002.

(17) Consists of 2,009,704 held by the NYBC, of which Mr. Tendler may be
considered the beneficial owner, 3,500 shares directly owned by Mr.
Tendler and 17,750 shares issuable upon the exercise of outstanding
options exercisable on or before June 14, 2002. Mr. Tendler disclaims
beneficial ownership of the shares held by NYBC.

(18) Consists of shares held by J.P. Morgan Partners LLC of which Dr. Wicker
may be considered the beneficial owner and 15,750 shares issuable upon the
exercise of outstanding options exercisable on or before June 14, 2002.
Dr. Wicker disclaims beneficial ownership of shares held by J.P. Morgan
Partners LLC except to the extent of his pecuniary interest therein.

(19) Includes 888,829 shares issuable upon the exercise of outstanding options
exercisable on or before June 14, 2002.

ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS.

In February 1998, Pall Corporation ("Pall") and VITEX entered into a
series of agreements (the "Pall Agreements") providing for, among other things,
collaboration on the development and marketing of systems employing our pathogen
reduction technologies for red blood cell and platelet concentrates. Pall is a
leading manufacturer and supplier of filtration products, including those
relating to the collection, preservation, processing, manipulation, storage and
treatment of blood and blood components. Under the Pall Agreements, Pall
receives exclusive worldwide distribution rights to all systems incorporating
pathogen reduction technology for red blood cells and platelets. We have also
agreed to share with Pall research, development, clinical and regulatory
responsibilities and will equally share profits and joint expenses from
operations after each party is reimbursed for its cost of goods. Pall research
funding in Fiscal Year 2001 totaled $5.8 million and we purchased production
related materials from Pall totaling $0.2 million during the year.

Upon execution of the Pall Agreements in February 1998 and at the time
of our initial public offering, Pall made equity investments in VITEX totaling
$9.0 million. In addition, the Pall Agreements provide that Pall will purchase
up to $17.0 million worth of our common stock in installments tied to the
achievement of specific development milestones ($10.0 million remaining at
December 29, 2001). Such equity investments by Pall will be made at the
prevailing market price per share. We reached equity milestones in December 2000
and December 1999 and accordingly, Pall purchased $4.0 million and $3.0 million,
respectively, of our common stock at the then market price. Mr. Hayward-Surry,
one of our directors, is the President and is a member of the Board of Directors
of Pall Corporation.

During Fiscal Year 2001, in anticipation of the Plasma Operations
divestiture described below, we terminated our last active technology license
from the New York Blood Center ("NYBC"). Prior to termination, we made royalty
payments to the NYBC in Fiscal Year 2001 totaling $0.7 million. Mr. Tendler, one
of our directors, is a member of the Board of Trustees and the Executive
Committee of NYBC.

As of April 15, 2002, Ampersand Ventures ("Ampersand") owned
approximately 34 percent of our outstanding stock, as described in Note 2 to the
Security Ownership by Management and Principle Stockholders Table. Messrs.
Charpie and Parker and Dr. Ackerman, our directors, are general partners in
Ampersand and, in the case of Mr. Charpie, managing general partner, of various
Ampersand funds (as more fully described in Note 2 to the Security Ownership by
Management and Principle Stockholders Table). As of April 15, 2002,
Messrs. Charpie and Parker may be considered beneficial owners of 33.6 percent
of our outstanding stock. Dr. Ackerman owned 1.9 percent of our outstanding
stock as of April 15, 2002.

On August 14, 2001, we completed the divestiture of our Plasma
Operations located in Melville, New York to Precision Pharma Services, Inc.
("Precision"), a newly-formed company owned by management of the Plasma
Operations and Ampersand. The Plasma Operations were
responsible for producing intermediate plasma fractions for Bayer and for viral
inactivation of transfusion plasma for the Red Cross. The total value of the
transaction was approximately $34.0 million, and the net book value of the
assets we divested to Precision was $39.1 million.

We entered into a consulting agreement in October 2000 with Dr.
Ackerman, Chairman of our Board of Directors and Chief Scientific Officer. Under
the terms of this agreement which renews annually, Dr. Ackerman received a total
of $0.1 million for his consulting services in Fiscal Year 2001. During Fiscal
Year 2001, we purchased $0.1 million in processing services from a company in
which Dr. Ackerman is an officer and an investor and in which Ampersand is also
an investor.

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned, thereto duly authorized on this 26th day of
April 2002.

V.I. TECHNOLOGIES, INC.

By: /s/ John R. Barr
----------------
John R. Barr
President and Chief Executive Officer

Pursuant to the requirements of the Securities Exchange Act of 1934,
this report has been signed below by the following persons on behalf of the
registrant and in the capacities and on the dates indicated.

Signature Title Date

/s/ John R. Barr President, Chief Executive Officer and April 26, 2002
------------------------------ Director (Principal Executive Officer)
John R. Barr

/s/ Samuel K. Ackerman, M.D. Chairman of the Board of Directors April 26, 2002
------------------------------
Samuel K. Ackerman, M.D.

/s/ Thomas T. Higgins Executive Vice President, Operations, April 26, 2002
------------------------------ (Principal Financial Officer and
Thomas T. Higgins Principal Accounting Officer)

/s/ Richard A. Charpie Director April 26, 2002
------------------------------
Richard A. Charpie

/s/ Jeremy Hayward-Surry Director April 26, 2002
------------------------------
Jeremy Hayward-Surry

/s/ Irwin Lerner Director April 26, 2002
------------------------------
Irwin Lerner

/s/ Joseph M. Limber Director April 26, 2002
------------------------------
Joseph M. Limber

/s/ Peter D. Parker Director April 26, 2002
------------------------------
Peter D. Parker

/s/ Doros Platika, M.D. Director April 26, 2002
------------------------------
Doros Platika, M.D.

/s/ David Tendler Director April 26, 2002
------------------------------
David Tendler